疑似ST段抬高型心肌梗死合并心源性休克患者内皮细胞及糖萼损伤生物标志物血浆浓度升高
该研究在1467例连续疑似STEMI患者中,对96%的患者于入院时检测反映内皮细胞损伤的可溶性血栓调节蛋白(sTM)和糖萼损伤的syndecan-1。入院时心源性休克(n=85)和导管室发生心源性休克(n=25)的患者sTM和syndecan-1水平高于无心源性休克患者(n=1299)。晚期心源性休克患者(n=58)sTM较高(8.8 vs 7.4 ng/mL,P=0.0004),但syndecan-1无差异(P=0.26)。sTM与晚期心源性休克发生无独立关联(OR 1.07,95%CI 0.99-1.16,P=0.09),sTM和syndecan-1均与30天死亡无独立关联。
要点
- 疑似STEMI患者入院时sTM和syndecan-1升高与入院时心源性休克(n=85)及导管室发生心源性休克(n=25)相关。
- 晚期心源性休克患者(n=58)sTM高于无心源性休克患者(中位数8.8 vs 7.4 ng/mL,P=0.0004),但syndecan-1无差异(P=0.26)。
- sTM与晚期心源性休克发生无独立关联(OR 1.07,95%CI 0.99-1.16,P=0.09)。
- sTM和syndecan-1均与30天死亡无独立关联(HR分别为1.06,95%CI 0.996-1.12,P=0.07;1.04,95%CI 0.99-1.08,P=0.12)。
- sTM和syndecan-1最高水平组30天死亡率最高(Plogrank<0.0001)。
适用人群与场景
- 连续1467例疑似STEMI患者,其中96%的患者检测了生物标志物。
- 按是否发生心源性休克分层,心源性休克患者再分为入院时心源性休克、导管室发生心源性休克和晚期心源性休克。
研究设计与关键结果
- 研究类型为在1467例连续疑似STEMI患者中检测入院时sTM和syndecan-1水平,96%的患者有检测结果。
- 入院时心源性休克患者(n=85)和导管室发生心源性休克患者(n=25)的sTM和syndecan-1水平高于无心源性休克患者(n=1299)。
- 晚期心源性休克患者(n=58)sTM中位数8.8 ng/mL(25th;75th百分位7.0;11.6)vs 无心源性休克患者7.4 ng/mL(6.0;9.0),P=0.0004;syndecan-1无差异(P=0.26)。
- sTM与晚期心源性休克发生无独立关联(OR 1.07,95%CI 0.99-1.16,P=0.09)。
- sTM和syndecan-1最高水平组30天死亡率最高(Plogrank<0.0001)。
- sTM和syndecan-1均与30天死亡无独立关联(HR sTM 1.06,95%CI 0.996-1.12,P=0.07;syndecan-1 1.04,95%CI 0.99-1.08,P=0.12)。
证据类型、等级与局限
- 证据类型:在连续疑似STEMI患者中检测入院时生物标志物的研究。
- 局限:原文未报告局限性。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「对床旁实践的改变」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Mortality in ST-elevation myocardial infarction (STEMI) patients developing cardiogenic shock (CS) during hospitalization is high. Catecholamines, ischemia, and inflammation (parameters present in CS) affect the endothelium. We hypothesized that plasma level of biomarkers reflecting endothelial damage would be associated with CS and mortality.
METHODS: In 96% of 1467 consecutive patients with suspected STEMI, biomarkers reflecting endothelial cell- (soluble thrombomodulin, sTM) and glycocalyx- (syndecan-1) damage were measured on admission. Patients were stratified by CS development or not. CS-Patients were substratified by CS on admission (admission-CS), CS developed in the catheterization laboratory (cath. lab.-CS), or late CS.
RESULTS: STEMI patients with admission-CS (n = 85) and cath.lab.-CS (n = 25) had higher levels of sTM and syndecan-1 compared with no-CS patients (n = 1,299). Late CS-patients (n = 58) had higher levels of sTM (median (25th; 75th percentile) 8.8 (7.0; 11.6) vs. 7.4 (6.0; 9.0) ng/mL, P = 0.0004) but not Syndecan-1 (P = 0.26) compared with no-CS patients. sTM was, however, not independently associated with late CS development (OR (95% CI) 1.07 (0.99-1.16), P = 0.09). Patients with the highest level of sTM and syndecan-1 had the highest 30-day mortality (Plogrank<0.0001). However, neither sTM nor Syndecan-1 was independently associated with 30-day mortality (HR (95% CI) sTM: 1.06 (0.996-1.12), P = 0.07; Syndecan-1: 1.04 (0.99-1.08), P = 0.12).
CONCLUSION: Patients with suspected STEMI patients and admission-CS/cath.lab.-CS had elevated admission levels of sTM and Syndecan-1 compared with no CS patients. Patients developing late CS had higher sTM plasma concentration compared with patients without shock. However, the biomarker levels were not independently associated with late CS and mortality.
参考来源
- Frydland M, Ostrowski SR, Møller JE, et al. Plasma Concentration of Biomarkers Reflecting Endothelial Cell- and Glycocalyx Damage are Increased in Patients With Suspected ST-Elevation Myocardial Infarction Complicated by Cardiogenic Shock. Shock. 2018. PMID: 29438221. doi:10.1097/SHK.0000000000001123
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。